

## Efficacy and safety on anti-cancer drug candidate of immune-checkpoint protein and cytokine fused platform

BIOonSYSTEMS



ONCOLOGY	Lead
Product Type	Recombinant Protein(Fc-Fusion)
Indication	Cancer
Target	Immune Checkpoint Inhibitors(Cancer cells) & Cytokine Receptor(Immune Cells)
MoA(Mechanism of Action)	Binding to Immune Checkpoint Inhibitors & Cytokine Receptor → Activation of Immune Cells → Killing Cancer Cells
Competitiveness	<ul style="list-style-type: none"> <li>• Synergic effect by blocking immune checkpoint inhibitors on cancer cells and activation/effector function of immune cells</li> <li>• Increase serum half-life by long-acting Fc construct</li> <li>• Combined modality therapy with immuno-ONCOLOGY drugs and targeted cancer drugs</li> </ul>
Development Stage	Lead
Route of Administration	Parenteral-Intravenous